The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors

被引：47

作者：

Membreno, Fernando E. ^{[1
]}

Lawitz, Eric J. ^{[1
]}

机构：

[1] Alamo Med Res, San Antonio, TX 78215 USA

来源：

CLINICS IN LIVER DISEASE | 2011年 / 15卷 / 03期

关键词：

Hepatitis C virus; NS5B nucleoside inhibitors; Non-nucleoside inhibitors; Polymerase inhibitors; HEPATITIS-C VIRUS; RNA-POLYMERASE INHIBITOR; ANTIVIRAL EFFICACY; HCVNS5B POLYMERASE; RESISTANCE; PROTEASE; INFECTION; PHARMACOKINETICS; PEGINTERFERON; TELAPREVIR;

D O I：

10.1016/j.cld.2011.05.003

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

This article introduces one of the most diverse classes of direct-acting antivirals for hepatitis C, the nucleoside and non-nucleoside NS5B polymerase inhibitors. Through a systematic review of the published literature, we describe their structure, mechanism of action, issues with resistance, and clinical effectiveness shown in the latest clinical trials. Direct-acting antiviral combination trials that have already shown some early promising results even in the setting of interferon-sparing antiviral regimens are discussed.

引用

页码：611 / +

页数：17

共 56 条

[21]

Klein CE, 2009, SAFETY TOLERABILITY

[22]

KOLYKHALOV A, 2010, 61 ANN M AM ASS STUD, pA1888

[23] Naturally Occurring Dominant Resistance Mutations to Hepatitis C Virus Protease and Polymerase Inhibitors in Treatment-Naive Patients [J].

Kuntzen, Thomas ;

Timm, Joerg ;

Berical, Andrew ;

Lennon, Niall ;

Berlin, Aaron M. ;

Young, Sarah K. ;

Lee, Bongshin ;

Heckerman, David ;

Carlson, Jonathan ;

Reyor, Laura L. ;

Kleyman, Marianna ;

McMahon, Cory M. ;

Birch, Christopher ;

Wiesch, Julian Schulze zur ;

Ledlie, Timothy ;

Koehrsen, Michael ;

Kodira, Chinnappa ;

Roberts, Andrew D. ;

Lauer, Georg M. ;

Rosen, Hugo R. ;

Bihl, Florian ;

Cerny, Andreas ;

Spengler, Ulrich ;

Liu, Zhimin ;

Kim, Arthr Y. ;

Xing, Yanming ;

Schneidewind, Arne ;

Madey, Margaret A. ;

Fleckenstein, Jaquelyn F. ;

Park, Vicki M. ;

Galagan, James E. ;

Nusbaum, Chad ;

Walker, Bruce D. ;

Lake-Bakaar, Gerond V. ;

Daar, Eric S. ;

Jacobson, Ira M. ;

Gomperts, Edivard D. ;

Edlin, Brian R. ;

Donfield, Sharyne M. ;

Chung, Raymond T. ;

Talal, Andrew H. ;

Marion, Tony ;

Birren, Bruce W. ;

Henn, Mattliew R. ;

Allen, Todd M. .

HEPATOLOGY, 2008, 48 (06) :1769-1778

[24] Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors [J].

Kwong, Ann D. ;

McNair, Lindsay ;

Jacobson, Ira ;

George, Shelley .

CURRENT OPINION IN PHARMACOLOGY, 2008, 8 (05) :522-531

[25] Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with Peg-IFN and ribavirin: Interim results of R7128 500mg BID for 28 days [J].

Lalezari, J. ;

Gane, E. ;

Rodriguez-Torres, M. ;

DeJesus, E. ;

Nelson, D. ;

Everson, G. ;

Jacobson, I. ;

Reddy, R. ;

Hill, G. Z. ;

Beard, A. ;

Symonds, W. T. ;

Berrey, M. M. ;

McHutchison, J. G. .

JOURNAL OF HEPATOLOGY, 2008, 48 :S29-S29

[26]

LALEZARI JP, 2010, 61 ANN M AM ASS STUD, pA34

[27] SAFETY, PHARMACOKINETICS AND ANTIVIRAL EFFECT OF BI 207127, A NOVEL HCV RNA POLYMERASE INHIBITOR, AFTER 5 DAYS ORAL TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C [J].

Larrey, D. ;

Benhamou, Y. ;

Lohse, A. W. ;

Trepo, C. ;

Moelleken, C. ;

Bronowicki, J-P. ;

Arasteh, K. ;

Bourliere, M. ;

Heim, M. ;

Enriquez, J. ;

Erhardt, A. ;

Zarski, J. -P ;

Wiest, R. ;

Gerlach, T. ;

Wedemeyer, H. ;

Berg, T. ;

Stern, J. ;

Wu, K. ;

Abdallah, N. ;

Nehmiz, G. ;

Boecher, W. ;

Steffgen, J. .

JOURNAL OF HEPATOLOGY, 2009, 50 :S383-S384

[28]

LARREY D, 2010, 45 ANN M EUR ASS STU

[29]

LAWITZ EJ, 2009, J HEPATOL S1, V50, pA92

[30]

LAWITZ EJ, 2010, 61 ANN M AM ASS STUD, pA31

← 1 2 3 4 5 6 →